EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate A

Ensembl ID : ENSIPUG00000001879
Gene Symbol: HTR5AA
4 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSIPUG00000011742
Gene Symbol: HTR5AB
3 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 7a

Ensembl ID : ENSIPUG00000018148
Gene Symbol: HTR7A
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSIPUG00000008275
Gene Symbol: LOC108275856
3 Cross references
184 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSIPUG00000023556
Gene Symbol: HTR1B
1 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSIPUG00000016152
Gene Symbol: HTR1E
1 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSIPUG00000023456
Gene Symbol: HTR1F
4 Cross references
142 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSIPUG00000012032
Gene Symbol: HTR2C
3 Cross references
154 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSIPUG00000000773
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSIPUG00000000785
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSIPUG00000001401
Gene Symbol: HTR4
4 Cross references
199 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSIPUG00000021804
Gene Symbol: HTR6
3 Cross references
114 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).